Evidence map›Paper›PMID 41240091›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

The German Cancer Consortium (DKTK) multi-center prospective phase 1/2

Frederik L Giesel, Stefan A Koerber, Boris Hadaschik, Selina Kiefer, Sarah Schwarzenboeck, Kambiz Rahbar, Thorsten Derlin, Christoph A Grott, Matthias Heck, Cordula Jilg and 21 more

Abstract readMulticenter StudyClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Localization of an ectopic hepatic parathyroid adenoma with [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Frederik L GieselDepartment of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Stefan A KoerberDepartment of Radiation Oncology, Barmherzige Brüder Hospital Regensburg, Regensburg, Germany.
Boris HadaschikDepartment of Urology, University Hospital Essen, Essen, Germany.
Selina KieferInstitute for Surgical Pathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
Sarah SchwarzenboeckDepartment of Nuclear Medicine, University Medical Centre, Rostock, Germany.
Kambiz RahbarDepartment of Nuclear Medicine, Münster University Hospital, Münster, Germany.
Thorsten DerlinDepartment of Nuclear Medicine, Hannover Medical School, Hanover, Germany.
Christoph A GrottDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Matthias HeckDepartment of Urology, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany.
Cordula JilgDepartment of Urology, Faculty of Medicine, University of Freiburg-Medical Centre, Freiburg, Germany.
Philipp T MeyerDepartment of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Juri RufDepartment of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Karl SchmidtABX-CRO, Dresden, Germany.
Joerg KotzerkeDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Christian la FougèreDepartment of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany.
Gerald ReischlDepartment of Preclinical Imaging and Radiopharmacy, University Hospital Tuebingen, Tuebingen, Germany.
Irene VirgoliniDepartment of Nuclear Medicine, University Hospital Innsbruck, Innsbruck, Austria.
Ken HerrmannDepartment of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.
Irene A BurgerDepartment of Nuclear Medicine, Kantonsspital Baden, Affiliated Hospital for Research and Teaching of the Faculty of Medicine of the University of Zurich, Baden, Switzerland.
Theo LorenziniDepartment of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany.
Martin WernerInstitute for Surgical Pathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
Albrecht StenzingerInstitute of Pathology, Division of Molecular Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Kristina SchwambornInstitute of Pathology, Technical University of Munich, School of Medicine, Munich, Germany.
Jan Philipp RadtkeDepartment of Urology, Medical Faculty, University Duesseldorf, Düsseldorf, Germany.
Markus HohenfellnerDepartment of Urology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.
Juergen DebusDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Wolfgang A WeberDepartment of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany.
Uwe HaberkornDepartment of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Klaus KopkaDivision of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany.
Matthias EiberDepartment of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany. matthias.eiber@tum.de.ORCID 0000-0003-2130-644X
68Ga-PSMA-11 DKTK trial contributors

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClinically accurate detection of prostate cancer (PCa) metastases is crucial for management of high-risk PCa patients scheduled for radical prostatectomy. We determine the safety and diagnostic accuracy of pre-operative

methodsInvestigator-initiated prospective multi-center multinational single-arm open-label phase 1/2 imaging trial (EuRadCT 2016-001815-19). Patients with high-risk PCa scheduled for prostatectomy were enrolled at 9 institutions in Germany, Austria, and Switzerland to undergo

results173 patients underwent

conclusionIn high-risk primary PCa,

fundingThe study was funded by the German Cancer Consortium (DKTK).

Indexed as

DipeptidesEdetic AcidOligopeptidesPositron Emission Tomography Computed TomographyProstatic NeoplasmsSafetyAgedGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedProspective StudiesDipeptidesEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptides68Ga-PSMA-11Diagnostic accuracyHigh risk prostate cancerPETRadiation therapy planningSafety

Identifiers

PMID41240091
PMCPMC13013323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.